home > news > 2008 > september > roche/bms study finds simcyp ‘the most sophisticated approach to simulations of clinical ddi’
Roche/BMS study finds Simcyp ‘the most sophisticated approach to simulations of clinical DDI’
Date: 19 Sep 2008
A new article published in the American Association of Pharmaceutical Scientists (AAPS) Journal reviews the experimental practices and likely future developments for the screening of potential drug-drug interactions caused by inhibition of cytochrome P450 (CYP) enzymes.
The authors, Stephen Fowler (F. Hoffman La-Roche) and Hongjian Zhang (Bristol-Myers Squibb), examine the methods for the in vitro evaluation of CYP inhibition and how resultant data can be used in ranking, extrapolation and DDI prediction.
As part of their discussions on human in vivo DDI prediction the authors state: “the Simcyp software package provides the most sophisticated approach to simulation of clinical DDI studies, allowing substrate and inhibitor concentrations to be modelled over the time of a simulated clinical study in a population of virtual individuals, each with their own enzymatic and physiological status parameters, to give a population-based estimate of the DDI risk. The inclusion of time-dependent inhibition and induction effects into the simulations offers the possibility to come even closer to the in vivo situation.”
The paper is entitled, ‘In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: Current status on methodologies and their utility for predicting drug-drug interactions’. Please click here for a link to the abstract and full text options.